Business Context and Reporting Period
Company: ADC Therapeutics SA (ADCT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: ADC Therapeutics is a commercial-stage global pioneer in antibody drug conjugates (ADCs). Its primary revenue-generating asset is ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is actively pursuing label expansion into earlier lines of DLBCL and indolent lymphomas via clinical trials (LOTIS-5, LOTIS-7) and has completed IND-enabling activities for a PSMA-targeting ADC (ADCT-241) for prostate cancer.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 |
|---|---|---|
| Total Revenue, Net | $81.4 | $70.8 |
| Product Revenues, Net | $73.6 | $69.3 |
| License Revenues and Royalties | $7.8 | $1.6 |
| Net Loss | $(142.6) | $(157.8) |
| Net Loss Per Share (Basic & Diluted) | $(1.12) | $(1.62) |
| Cash and Cash Equivalents (Year End) | $261.3 | $250.9 |
| Operating Cash Flow | $(141.2) | $(123.8) |
| Debt Obligations | ||
| Senior Secured Term Loans (Carrying Value) | $115.5 | $113.6 |
| Deferred Royalty Obligation (HCR) | $333.6 | $326.7 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 14.9% to $81.4 million. Product revenue grew 6.2% driven by higher sales prices. License revenue surged 401.3% to $7.8 million, primarily due to a $5.0 million milestone payment from Sobi following Health Canada's conditional approval of ZYNLONTA.
- Restructuring Costs: The company incurred $13.1 million in restructuring, impairment, and other related costs in 2025 (none in 2024). This followed a strategic reprioritization plan ("2025 Restructuring") involving a ~30% global workforce reduction and the closure of the UK facility.
- Operating Expenses: Total operating expenses remained relatively flat at $202.9 million. Research and Development (R&D) expenses decreased 5.1% to $104.0 million due to the discontinuation of certain programs (e.g., ADCT-601) and restructuring. Selling and marketing expenses decreased slightly by 1.5%.
- Non-Cash Adjustments: A significant non-cash gain of $22.2 million was recorded in "Other, net" related to a cumulative catch-up adjustment of the deferred royalty obligation to HCR, driven by revised revenue forecasts.
- Financing Activities: The company raised significant capital through two private placements in 2025 (June and October), generating net proceeds of approximately $150.7 million combined.
Guidance, Outlook, and Risks
- Clinical Catalysts:
- LOTIS-5 (Phase 3): Enrollment completed in 2024. Topline data is expected in the first half of 2026. Success is critical for confirming accelerated approval and expanding into 2L+ DLBCL.
- LOTIS-7 (Phase 1b): Investigating ZYNLONTA in combination with glofitamab. Enrollment of ~100 patients at the selected dose is expected in the first half of 2026.
- Investigator-Initiated Trials (IITs): Encouraging data presented for ZYNLONTA in Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL).
- Liquidity: As of December 31, 2025, the company held $261.3 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next 12 months.
- Key Risks:
- Regulatory Approval: Continued approval of ZYNLONTA is contingent on the success of the LOTIS-5 confirmatory trial. High rates of early censoring in the trial remain a concern for data interpretability.
- Debt Covenants: The company is subject to restrictive covenants under its Loan Agreement, including a revenue covenant requiring minimum U.S. net sales if market cap is below $650 million, and a minimum cash balance covenant ($60 million).
- Royalty Obligations: The HCR Agreement requires royalty payments on net sales and licensing revenue, capped at 2.5x the investment amount ($750 million). A change in control triggers a significant payment obligation ($150 million - $200 million).
- Manufacturing: Reliance on third-party CMOs for all manufacturing introduces supply chain risks.
Investor Verification Checklist
- LOTIS-5 Trial Status: Verify the timeline and preliminary data readout for the Phase 3 LOTIS-5 trial, specifically addressing the impact of early patient censoring on the primary endpoint (Progression-Free Survival).
- Cash Burn Rate: Monitor quarterly operating cash flow to ensure the $261.3 million cash balance remains sufficient given the ongoing R&D spend and debt service requirements.
- Debt Covenant Compliance: Confirm compliance with the Loan Agreement's revenue covenant (minimum U.S. net sales) and cash balance covenant ($60 million) in upcoming quarters.
- HCR Royalty Liability: Review the assumptions used for the deferred royalty obligation valuation, as changes in revenue forecasts can lead to significant non-cash volatility in earnings.
- Commercial Partnerships: Track commercialization progress and royalty milestones with partners Sobi (EMEA), TPC (Japan), and Overland (Greater China).